Management of Post-Facelift Facial Paralysis With Botulinum Toxin Type A

2021 ◽  
Author(s):  
Alessandra Grassi Salles ◽  
Wellington Menezes Mota ◽  
Adelina Fátima do Nascimento Remigio ◽  
Antonio Carlos Herrmann de Andrade ◽  
Rolf Gemperli
Keyword(s):  
Botulinum Toxin ◽  
Nerve Injury ◽  
Botulinum Toxin Type A ◽  
Type A ◽  
Botulinum Toxin Type ◽  
Single Session ◽  
Nerve Lesions ◽  
Outcomes Evaluation ◽  
The Face ◽  
Upper Third

Abstract Background Facial nerve injury after facelift is rare; hence, its treatment is poorly established. Botulinum toxin type A (BTXA) can be used to resolve the asymmetry. There is no protocol in the literature about the best timing for this treatment, injection sites or recommended dose. Objectives Propose a protocol to guide the management of asymmetries post-facelifts. Methods Fifteen patients with post-rhytidectomy facial palsies were treated in the non-paralyzed side with BTXA. After analysis of the smile deviation vectors, it is possible to identify the muscles that should be treated. The dose varied from 1-2 Uv/point. Patients were examined after 15 days for outcomes evaluation, and “touch-up” if needed. Patients were re-treated after 5-6 months in case of asymmetry recurrence. Results Symmetry was achieved in all cases. Six patients had definitive nerve lesions and needed to be treated every 6 months after the first session. Five patients had lesions affecting the upper third of the face, four of them were definitive nerve lesions. Two of the four patients who were treated less than 2 weeks after surgery recovered early from the post-facelift paralysis and developed reversed asymmetry due to the BTXA. In seven patients, the post-facelift asymmetry was due to neuropraxis: the recovery from the nerve injury and BTXA treatment occurred symmetrically on both sides of the face in the following months, after one single session. Conclusions Asymmetries post-facelifts were successfully managed with the proposed protocol. Best time for injection was 2-4 weeks after surgery.

scholarly journals Botulinum Toxin Type A Reconstituted with Lidocaine: A Report of 1000 Consecutive Cases

2021 ◽  
Vol 11 (10) ◽  
pp. 4491
Author(s):  
Pierfrancesco Bove ◽  
Vincenzo Santillo ◽  
Giuseppe Colella ◽  
Rita Vitagliano ◽  
Romolo Fragola ◽  
...  
Keyword(s):  
Botulinum Toxin ◽  
Botulinum Toxin Type A ◽  
Type A ◽  
Botulinum Toxin Type ◽  
Immediate Feedback ◽  
The Face ◽  
Increasing Demand ◽  
Almost All ◽  
Upper Third ◽  
Minimally Invasive Methods

(1) Background: There is an increasing demand for a reversal of the aging process and, nowadays, more patients are seeking minimally invasive methods instead of surgery to meet this goal. The purpose of this paper is to evaluate the predictability of the off-label aesthetic use of botulinum toxin type A (BoNTA) reconstituted with lidocaine. (2) Methods: One thousand treatments, between January 2010 and January 2020, with BoNTA reconstituted with lidocaine for the rejuvenation of the upper third of the face, were performed and retrospectively evaluated. (3) Results: A few seconds after the BoNTA injections, the effect of muscle paralysis was seen in all cases; this allowed providing an optimal symmetric result with no need for a touch-up procedure at the control after three weeks. A burning sensation during the injections was claimed by almost all patients. Major complications were not registered. No touch-up procedures were required. (4) Conclusions: The results of this study show how the reconstitution of BoNTA with lidocaine may avoid imperfect results after the injections; the immediate feedback on the extent of paralysis to be expected from the chemodenervation action of BoNTA allows the physician to have immediate control of the final result.

scholarly journals Potentialities of botulinum therapy in cosmetology

2020 ◽  
Vol 96 (5) ◽  
pp. 19-23
Author(s):  
O. M. Kapuler
Keyword(s):  
Botulinum Toxin ◽  
Botulinum Toxin Type A ◽  
Modern Society ◽  
Type A ◽  
Botulinum Toxin Type ◽  
Scientific Data ◽  
The Body ◽  
The Face ◽  
Negative Effect ◽  
Release Of Acetylcholine

The desire to maintain youth as long as it possible in modern society, especially among women of working age, is primarily due to the desire to be in demand, well-groomed and attractive. Currently, there are 5 main methods that contribute to improving the condition of the skin of the face, namely: the method using professional cosmetics, chemical peels, mesotherapy, treatment with an injection of botulinum toxin type A (BTA) and intradermal implants based on hyaluronic acid. The aim of the literature review was to analyze the latest scientific data on the possibility of botulinum therapy in cosmetology. Wrinkles of open areas of the body (primarily on the face and in the decollete) have a negative effect on the emotional background and quality of life of women. In this regard, recently there has been a significant increase in demand for aesthetic medicine services, one of the areas of which is botulinum therapy (BT). Botulinum toxin type A (BTA) is a powerful neurotoxin that inhibits the release of acetylcholine in the neuromuscular junction. Injections of small doses of botulinum toxin type A into targeted mimic muscles cause their relaxation, which smoothes the underlying layer of the skin, thereby regressing mimic wrinkles. Today, according to officially approved indications, it is used in cosmetology, botulinum therapy is used to correct mimic wrinkles in the upper third of the face, drooping corners of the mouth, in the complex correction of the face oval, in the treatment of axillary and palmar hyperhidrosis. Blocking a tear mediator like acetylcholine, not only the presynaptic membranes of neuromuscular synapses are rich, but also many anatomical structures, such as glandular tissue (sweat, other glands, etc.). This commonality of the mechanism of action on various physiological processes in our body allows us to make an assumption about the great potential of botulinum therapy in the treatment of a number of diseases associated with impaired neuromuscular conduction.

Use of Botulinum Toxin Type A Injection for Neuropathic Pain after Trigeminal Nerve Injury

Pain Medicine ◽  
2010 ◽  
Vol 11 (4) ◽  
pp. 630-632 ◽  
Author(s):  
Seung Hyun Yoon ◽  
Robert L. Merrill ◽  
Jong Hoon Choi ◽  
Seong Taek Kim
Keyword(s):  
Neuropathic Pain ◽  
Botulinum Toxin ◽  
Nerve Injury ◽  
Trigeminal Nerve ◽  
Botulinum Toxin Type A ◽  
Type A ◽  
Botulinum Toxin Type

Efficacy of Botulinum Toxin Type A in Improving Scar Quality and Wound Healing: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

2019 ◽  
Vol 40 (5) ◽  
pp. NP273-NP285 ◽  
Author(s):  
Xiaoshuang Guo ◽  
Guodong Song ◽  
Dong Zhang ◽  
Xiaolei Jin
Keyword(s):  
Wound Healing ◽  
Botulinum Toxin ◽  
Adverse Events ◽  
Meta Analysis ◽  
Botulinum Toxin Type A ◽  
Type A ◽  
Botulinum Toxin Type ◽  
Control Group ◽  
The Face ◽  
Scar Quality

Abstract Background Botulinum toxin type A-induced “chemoimmobilization” has long been utilized for improved scar quality and wound healing; however, current evidence is limited to small studies, and evidence-based information is inadequate to make well-informed decisions. Objectives The purpose of this study was to evaluate the efficacy of botulinum toxin type A (BTA) to improve scars and wound healing. Methods The authors searched databases, including Pubmed, Embase, and Cochrane Library, to identify randomized clinical trials (RCTs) that compared outcomes of surgical scars and wounds treated with BTA vs those treated with blank or placebo controls. The Visual Analog Scale, Vancouver Scar Score, scar width, and reported patient satisfaction were utilized in evaluating outcomes. Adverse events were also recorded. Results Eleven RCTs involved a total of 486 cases (374 patients). Quantitative synthesis suggested that compared with the control group, patients in the BTA treatment group had significantly higher Visual Analog Scale scores (mean difference [MD] = 1.30, 95% confidence interval [CI]: 1.05 to 1.55), lower Vancouver Scar Scores (MD = −1.62, 95% CI: −2.49 to −0.75, P = 0.0003), and thinner scars (MD = −0.15, 95% CI: −0.20 to −0.11, P < 0.00001). Patient satisfaction was higher in the BTA group than in the control group (risk ratio: 1.25, 95% CI: 1.06 to 1.49, P = 0.01). Trivial adverse events were reported. Conclusions This meta-analysis of RCTs provides reliable evidence that BTA injection is superior to placebo or blank control group in improving scar quality and wound healing in the face and neck for Asians, and negative outcomes for BTA treatment in these patients include only trivial adverse events. However, inadequate evidence supports utilization of BTA in Caucasians for primary surgical scars or for scars in locations other than the face and neck. Further studies on the standardized injection regimen and technique of BTA are warranted for clinical practice. Level of Evidence: 1

scholarly journals Botulinum Toxin Type A for the Treatment of Hyperkinetic Lines of the Face

2012 ◽  
Vol 12 (2) ◽  
pp. 173-183 ◽  
Author(s):  
Dinesh Singh Chauhan ◽  
K. M. Cariappa ◽  
Yadavalli Guruprasad
Keyword(s):  
Botulinum Toxin ◽  
Botulinum Toxin Type A ◽  
Type A ◽  
Botulinum Toxin Type ◽  
The Face

scholarly journals Potentialities of botulinum therapy in cosmetology

2020 ◽  
Vol 96 (5) ◽  
pp. 19-23
Author(s):  
O. M. Kapuler
Keyword(s):  
Botulinum Toxin ◽  
Botulinum Toxin Type A ◽  
Modern Society ◽  
Type A ◽  
Botulinum Toxin Type ◽  
Scientific Data ◽  
The Body ◽  
The Face ◽  
Negative Effect ◽  
Release Of Acetylcholine

The desire to maintain youth as long as it possible in modern society, especially among women of working age, is primarily due to the desire to be in demand, well-groomed and attractive. Currently, there are 5 main methods that contribute to improving the condition of the skin of the face, namely: the method using professional cosmetics, chemical peels, mesotherapy, treatment with an injection of botulinum toxin type A (BTA) and intradermal implants based on hyaluronic acid. The aim of the literature review was to analyze the latest scientific data on the possibility of botulinum therapy in cosmetology. Wrinkles of open areas of the body (primarily on the face and in the decollete) have a negative effect on the emotional background and quality of life of women. In this regard, recently there has been a significant increase in demand for aesthetic medicine services, one of the areas of which is botulinum therapy (BT). Botulinum toxin type A (BTA) is a powerful neurotoxin that inhibits the release of acetylcholine in the neuromuscular junction. Injections of small doses of botulinum toxin type A into targeted mimic muscles cause their relaxation, which smoothes the underlying layer of the skin, thereby regressing mimic wrinkles. Today, according to officially approved indications, it is used in cosmetology, botulinum therapy is used to correct mimic wrinkles in the upper third of the face, drooping corners of the mouth, in the complex correction of the face oval, in the treatment of axillary and palmar hyperhidrosis. Blocking a tear mediator like acetylcholine, not only the presynaptic membranes of neuromuscular synapses are rich, but also many anatomical structures, such as glandular tissue (sweat, other glands, etc.). This commonality of the mechanism of action on various physiological processes in our body allows us to make an assumption about the great potential of botulinum therapy in the treatment of a number of diseases associated with impaired neuromuscular conduction.

The use of botulinum toxin type a in the acute phase of facial nerve injury after neurosurgical surgery

2014 ◽  
Vol 78 (6) ◽  
pp. 50 ◽  
Author(s):  
O. R. Orlova ◽  
M. A. Akulov ◽  
D. Iu. Usachev ◽  
S. V. Taniashin ◽  
V. O. Zakharov ◽  
...  
Keyword(s):  
Botulinum Toxin ◽  
Facial Nerve ◽  
Nerve Injury ◽  
Acute Phase ◽  
Botulinum Toxin Type A ◽  
Type A ◽  
Botulinum Toxin Type ◽  
Facial Nerve Injury
Sign in / Sign up

Export Citation Format

Share Document